FindTrial
Sign In

Anti-D(IgM+IgG) Clinical trial

Anti-D(IgM+IgG) Clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17011975
Enrollment
Unknown
Registered
2017-07-13
Start date
2017-08-31
Completion date
Unknown
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Typing

Interventions

Gold Standard:Refer to Chapter 5, "Rh Blood Type Identification, 124-126" in the National Clinical Practice (Fourth Edition). "To use anti-D (IgM) antibodies to detect Rh antigen in erythrocytes in s
Index test:Comparison&#32
Reagents:&#32
Anti-D&#32
(IgM&#32
+&#32
IgG)&#32
Blood&#32
Forming&#32
Reagents&#32
(Monoclonal&#32
Antibodies)&#32
Millipore&#32
(UK)&#32
Limited&#32
Production

Sponsors

Shanghai 6th People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: No limit in gender, age or disease.

Exclusion criteria

Exclusion criteria: Do not collect blood samples collected by the same patient at different times. If such a situation is found, the test result should not be accepted.

Design outcomes

Primary

MeasureTime frame
Agglutination;—

Countries

China

Contacts

Public ContactWang Lingling

Shanghai Hemo-Pharmaceutical & Biological Co.,Ltd

51300098@163.com+86 021-31033800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026